Page 89 - Read Online

Lv. J Transl Genet Genom 2021;5:414-22 Journal of Translational
DOI: 10.20517/jtgg.2021.34
Genetics and Genomics

Review Open Access

The effect of HMGB1 and RAGE on the
clinicopathological and prognostic features of

prostate cancer

Dao-Jun Lv
Guangdong Key Laboratory of Urology, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital
of Guangzhou Medical University, Guangzhou 510230, Guangdong, China.

Correspondence to: Prof. Dao-Jun Lv, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of
Guangzhou Medical University, Kangda Road 1#, Haizhu District, Guangzhou 510230, Guangdong, China. E-mail:
daojunlv88@gzhmu.edu.cn
How to cite this article: Lv DJ. The effect of HMGB1 and RAGE on the clinicopathological and prognostic features of prostate
cancer. J Transl Genet Genom 2021;5:414-22. https://dx.doi.org/10.20517/jtgg.2021.34
Received: 7 Jul 2021 First Decision: 16 Aug 2021 Revised: 6 Sep 2021 Accepted: 9 Sep 2021 Published: 5 Nov 2021

Academic Editor: Sanjay Gupta Copy Editor: Yue-Yue Zhang Production Editor: Yue-Yue Zhang

Abstract
As a DNA-binding protein, high mobility group box 1 (HMGB1) has been shown be involved in various biological
activities, including transcription regulation, DNA repair, genomic stability, and extracellular signaling.
Accumulating evidence indicates that HMGB1 has an important role in biological processes in cancer. Moreover,
HMGB1 has been shown to have intracellular and extracellular roles, activating key cancerogenic signaling
pathways. The main signal pathway is activated via the interaction of HMGB1 with its receptor, receptor for
advanced glycation end-products (RAGE). In addition, overexpression of HMGB1/RAGE occurs in certain types of
primary tumors and has been linked to increased metastasis and poorer prognosis. In our previous research, we
demonstrated that co-expression of HMGB1 and RAGE is associated with cancer progression and poor patient
outcome in prostate cancer (PCa). Together with the recent published evidence, we describe and speculate on the
character of the HMGB1/RAGE axis in PCa progression and elaborate on future prospects for the application of
potential strategies to target HMGB1 in PCa therapy.

Keywords: High mobility group box 1, receptor for advanced glycation end-products, prostate cancer

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.

www.jtggjournal.com